Delving into the Latest Updates on elbion AG with Synapse

Overview

Basic Info

Introduction

elbion AG is a company that specializes in discovering and developing innovative small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical needs. Their lead product candidate, AWD 12-281, is a topical inhibitor and has been licensed to GlaxoSmithKline for further development and commercialization. The company's focus is on identifying novel chemistries, assays, and mechanisms of action, as well as utilizing in-house animal disease models, particularly in the areas of PDE inhibitors and CNS modulators. Founded in 2002, elbion AG is headquartered in Radebeul, Germany.

A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 weeks (8 + 4 weeks) versus placebo and versus 4mg tolterodine given once daily in patients with incontinent overactive bladder (OAB)

Start Date21 Feb 2007

Sponsor / Collaborator

elbion AG

NCT00439192 / TerminatedPhase 2

A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)

This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.

Start Date01 Feb 2007

Sponsor / Collaborator

elbion AG

NCT00322803 / TerminatedPhase 2

International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment

This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.

Start Date01 May 2006

Sponsor / Collaborator

elbion AG

100 Clinical Results associated with elbion AG

Login to view more data

0 Patents (Medical) associated with elbion AG

Login to view more data

100 Deals associated with elbion AG

Login to view more data

100 Translational Medicine associated with elbion AG

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

8

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AWD-5239 ( 5-HT2 receptor )	Cognition Disorders More	Discontinued
ELB-139 ( GABAA receptor )	Anxiety Disorders More	Discontinued
ELB-245	Urinary Bladder, Overactive More	Discontinued
AWD-140190 ( SCNA )	Epilepsy More	Discontinued
Imepitoin ( GABAA receptor )	Epilepsy More	Discontinued